JP6590233B1 - Skin disease therapeutic agent and method for producing the same - Google Patents

Abstract

Disclosed is a skin disease therapeutic agent mainly comprising a pesticide capable of more effectively suppressing itching and inflammation such as atopic dermatitis, and a method for producing the same. A therapeutic agent for skin diseases is harmful by distillation and purification with a pill extract obtained by extracting from a pill resin with a 40 wt% to 70 wt% ethanol solution or a 40 wt% to 70 wt% butylene glycol solution. Contains wood vinegar or bamboo vinegar from which the substance has been removed as an active ingredient. [Selection] Figure 3

Description

  TECHNICAL FIELD The present invention relates to a skin disease therapeutic agent mainly composed of an ablating drug effective for the treatment of skin diseases associated with itching and inflammation such as atopic dermatitis, eczema and rash, and a method for producing the same.

  Recently, there are many factors around us that can cause allergic diseases. For example, the number of people suffering from allergic diseases is increasing due to building materials, clothing, food, and living environment. Among them, the number of patients suffering from skin diseases such as atopic dermatitis is increasing rapidly.

  For the treatment of allergic skin diseases, steroid-containing therapeutic drugs are mainly used, but steroids have side effects, and many patients feel anxious about long-term use. For this reason, there is a strong demand for the emergence of a safe and safe therapeutic agent that has few side effects even after long-term use and can provide a sufficient therapeutic effect.

  In developing countries, many people get infected with skin diseases such as insect bites and rashes from unsanitary environments. In order to prevent such skin diseases, it is preferable to use a disinfectant for outer skin.

For example, pills are reddish brown vegetable rubber resins that are naturally dried from the bark of the plants of the genus Orranaceae from Arabia and Africa, and pills have long been prized, and expensive fragrances in the Middle East and the Mediterranean. In addition to raw materials for perfumes and cosmetics, it was used in coating agents and preservatives. Today, pills are mainly used as a dentifrice, a raw material for perfumes and essential oils, and as a protective agent for pharmaceuticals. Furthermore, it has been used as a bactericidal agent having mild bactericidal, astringent, and wind-inducing action, a wind-inducing agent that discharges gas in the gastrointestinal tract, and a tincture that relieves inflammation in the oral cavity.
In addition, it is known that essential oil extracted from a pesticide resin by steam distillation can be used for the treatment of wounds and inflammation and aromatherapy.

  An example of a disinfectant for skin is ethanol. This ethanol has a bactericidal effect and is effective against vegetative bacteria (gram-positive bacteria, gram-negative bacteria), yeasts, viruses and the like at the concentration used. Similarly, butylene glycol (1,3-butylene glycol) is known as a moisturizer and antibacterial agent.

  These ethanol and butylene glycol are used as an extractant together with water in the production of an extract from a plant.

  For example, in "Recovery accelerating agent from adverse effects of stress and topical skin preparation containing the same" in Patent Document 1, many plants of Chinese herbal medicines including kanranaceae are used as a recovery accelerating agent or a topical skin preparation. It has been proposed to be used as And in this patent document 1, the improvement effect of the atopic dermatitis by the skin lotion containing the methanol extract of the leguminous confectionery ginger and the ginger department ginger, and the methanol extract of the sea urchinaceae Kangkou and the leguminous kudzu are included. The cream has been shown to improve sensitive skin.

  Patent Document 2 proposes to use Chinese herbal medicine and herbs as components of an itching-preventive skin external preparation, and among them, a dip medicine is mentioned. And it has been proposed that the effect of preventing itchiness is further improved by using a traditional Chinese medicine or herb together with glycyrrhizic acid.

  Patent Document 3 “Histamine release inhibitor and skin disease treatment agent” is characterized by containing, as an active ingredient, myrrh extract obtained by extracting from myrrh resin from ethanol or an ethanol solution having an ethanol concentration of 70% or more. Histamine release inhibitors or skin disease treatment agents have been proposed.

JP 2001-192338 A JP 2003-55241 A JP 2005-170829 A

  However, these Patent Documents 1 and 2 do not clarify which Chinese herbal medicine, Japanese herbal medicine, herbs and the like have their effects. It is not clarified what the therapeutic effect can be obtained by using what or how many of herbal medicines, Japanese herbs, and herbs. In addition, it is not clarified by what kind of effect the effect of preventing stagnation is obtained. No specific verification has been made, and no therapeutic agent that actually has a therapeutic effect has been identified.

Patent Document 3 verifies the histamine release inhibitory action and has verified that there is a histamine release inhibitory effect in the myrrh extract concentration range of 0.56 × 10 ^{−9 to} 0.56 × 10 ⁻⁵ . .

Further, there is a symptom improving effect of dermatitis in the concentration range of validation is performed of the symptoms improvement of dermatitis, myrrh extract concentration 0.7 × ^{10 -4} ~0.175 × ¹⁰ -4 in Patent Document 3 It has been verified. In particular, it is verified that the skin inflammation suppression effect is high at the lowest concentration of 0.175 × 10 ⁻⁴ . In preliminary experiments, it has been verified that too high myrrh concentration leads to exacerbation of dermatitis.

  It is also considered that there is a possibility that components that are effective in suppressing skin inflammation and components that exacerbate inflammation such as tar content are mixed in the ethanol extract component of myrrh.

  From the results of the verification performed in Patent Document 3, it can be seen that the concentration range having an inhibitory effect on histamine release does not match the concentration range having an effect of improving dermatitis symptoms. That is, it is suggested that it is difficult for one therapeutic agent to achieve both the itching prevention effect and the inflammation suppression effect of the skin.

  Atopic dermatitis, urticaria, contact dermatitis, seborrheic dermatitis, dermatitis, etc.The characteristic of dermatitis is skin inflammation accompanied by strong itching. Both anti-inflammatory effects are required.

  In other words, a therapeutic agent for atopic dermatitis comprising as an active ingredient a myrrh extract obtained by extracting from myrula resin recommended in Patent Document 3 from ethanol or an ethanol solution having an ethanol concentration of 70% or more is one therapeutic agent. It is impossible to obtain anti-itching and anti-inflammatory effects at the same time, and it is incomplete as a therapeutic agent for atopic dermatitis.

  The inventor of the present invention has intensively studied in view of such a situation. A person infected with a skin disease in a developing country tends to be injured as a result of scratching the part, and is easily infected from this wound part. Such further deterioration of the skin disease can be considered. Even if a person who is infected with a skin disease does not receive a formal diagnosis by a dermatologist, it is possible to apply a bactericidal or antibacterial agent to the skin disease or wound area. We focused on the fact that it can prevent the deterioration caused by the bacteria and suppress inflammation by the natural healing action of the person.

  The present invention has been developed to solve such problems. That is, an object of the present invention is to use an extract having a bactericidal and antibacterial effect for extraction of a pill of a vegetable rubber resin, so that the manufacturing time can be shortened and the manufacturing cost can be reduced. An object of the present invention is to provide a therapeutic agent for skin diseases mainly composed of a pesticide capable of more effectively suppressing itching and inflammation such as flame, and a method for producing the same.

The therapeutic agent for skin diseases according to the first aspect of the present invention is a pill extract obtained by dissolving at least a part of a pill resin in a 40 wt% to 70 wt% butylene glycol solution at a temperature condition of 10 to 50 ° C. ,
And acetic acid solution the plants such as wood vinegar or bamboo vinegar solution as a raw material, is the active ingredient,
The mixing ratio of the gallic extract and the acetic acid solution is such that the ratio of the acetic acid solution is 0.5 to 2 with respect to the ratio 1 of the gallic extract,
Part of the butylene glycol solution used for the extract contains as a moisturizing active ingredient .

The therapeutic agent for skin disease of the second aspect of the present invention is a pill extract obtained by dissolving at least part of a pill resin in a 40 wt% to 70 wt% ethanol solution at a temperature condition of 10 to 50 ° C ,
And acetic acid solution the plants such as wood vinegar or bamboo vinegar solution as a raw material, is the active ingredient,
The mixing ratio of the gallic extract and the acetic acid solution is such that the ratio of the acetic acid solution is 0.5 to 2 with respect to the ratio 1 of the gallic extract,
A part of the ethanol solution used for the extract contains as a sterilizing active ingredient having volatility .

Bromelain can be blended with the skin disease therapeutic agent.
The dosage form of the skin disease therapeutic agent is any of a liquid, cream, emulsion, ointment or poultice.

The method for producing a skin disease therapeutic agent of the present invention produces a pilling resin by drying the sap of a bark of a plant of the genus Mylanaceae,
In the temperature condition of 10-50 ° C. with a butylene glycol solution, extract the pilling extract from the pilling resin,
Partial concentration of the pill extract , leaving the extract extracted as the butylene glycol solution as a moisturizing active ingredient,
An acetic acid solution made from a plant such as wood vinegar or bamboo vinegar is used as the gallic extract , and the acetic acid solution has a mixing ratio of the gallic extract and the acetic acid with respect to the ratio 1 of the gallic extract. It mix | blends so that the ratio may become 0.5-2 , It is characterized by the above-mentioned.

Alternatively , in the method for producing a skin disease therapeutic agent of the present invention, a sap of a bark of a plant of the genus Mylanaceae is dried to produce a pesticide resin,
In the temperature condition of 10-50 ° C. with an ethanol solution, the pilling solution is extracted from the pilling resin,
Concentrating part of the pill extract , leaving the extract extracted as the ethanol solution as a sterilizing active ingredient having volatility,
An acetic acid solution made from a plant such as wood vinegar or bamboo vinegar is used as the gallic extract , and the acetic acid solution has a mixing ratio of the gallic extract and the acetic acid with respect to the ratio 1 of the gallic extract. It mix | blends so that the ratio may become 0.5-2 , It is characterized by the above-mentioned.
It is preferable to use an emulsifier when an acetic acid solution such as a wood vinegar solution or a bamboo vinegar solution is added to the pill extract.

Since the therapeutic agent for skin diseases of the present invention contains an extract of pills and an acetic acid solution made from plants such as wood vinegar or bamboo vinegar as active ingredients, atopic dermatitis, eczema, urticaria, psoriasis, prurigo For various skin diseases such as trauma, burns, insect bites, rashes, rashes and sensitive skin, inflammation and itching can be suitably suppressed, and there are few side effects and excellent safety.
In particular, by containing an extract extracted as a butylene glycol solution or an ethanol solution as an active ingredient without concentrating it, the aroma and refreshing feeling due to the volatile components derived from the cabbage act suitably.

  In the method for producing a skin disease therapeutic agent of the present invention, bactylene glycol or ethanol having an antibacterial and antibacterial effect is used as an extract to extract a pill of a vegetable rubber resin. Cost can be reduced. Moreover, the function of sterilizing and disinfecting the skin surface can be enhanced.

FIG. 3 is a flowchart showing a production method using an extraction step with a butylene glycol solution of Example 1. 6 is a flowchart showing a production method using an extraction step with an ethanol solution in Example 2. FIG. 3 is a graph showing the skin inflammation inhibitory effect of Conditioner 1. It is a photograph which shows the condition where the skin disease therapeutic agent of this invention was apply | coated to the affected part of a person, and a thing like sweet juice rose on the affected part surface after progress for a predetermined time. It is the photograph which applied and treated the skin disease therapeutic agent of this invention on the head of a 5-year-old girl, (a) is the state before a treatment, (b) is the state 30 days after a treatment. It is the photograph which shows the state which apply | coated the skin disease therapeutic agent of this invention on the back of the hand of a 9-year-old boy, and is a state before a treatment, (b) is a state 18 days after a treatment. It is the photograph which shows the state which apply | coated and treated the skin disease therapeutic agent of this invention to the location where the abdominal wound of the 9-year-old boy was suppurated, (a) is the state before treatment, (b) is the state after treatment. It is. It is a photograph which shows the state which apply | coated and treated the skin disease therapeutic agent of this invention to the location where the wound of the finger of 11-year-old boy was suppurated, (a) is the state before treatment, (b) is the state after treatment. It is. It is the photograph which shows the state which apply | coated and treated the skin disease therapeutic agent of this invention to the site | part where the wound of the back head of a 1-and-a-half-year-old girl was suppurated, (a) is a state before treatment, (b) is after treatment. The state after 18 days. It is the photograph which shows the state which apply | coated and treated the skin disease therapeutic agent of this invention to the site | part where the wound of the back head of a 2-year-old girl's infant suppurated, (a) is a state before treatment, (b) is after treatment. State. It is the photograph which shows the state which apply | coated and treated the skin disease therapeutic agent of this invention on the back head of a 13-year-old boy, (a) is the state before treatment, (b) is the state after treatment. It is the photograph which shows the state which apply | coated and treated the skin disease therapeutic agent of this invention to the abdomen of a 15-year-old boy, (a) is the state before treatment, (b) is the state after treatment. It is a photograph which shows the state which apply | coated and applied the skin disease therapeutic agent of this invention to the arm and palm of a 13-year-old boy, (a) is the state before treatment, (b) is the state after treatment. It is a photograph which shows the state which apply | coated the skin disease therapeutic agent of this invention around the mouth of a 12-year-old girl, and was treated, (a) is the state before treatment, (b) is the state after treatment.

  The present invention is a dermatological treatment agent containing a pesticide extract obtained by extraction from a pesticide resin with butylene glycol or an ethanol solution, and an acetic acid solution made from plants such as wood vinegar or bamboo vinegar. The pilling resin is an oily and rubbery resin that can be taken from the trunk of the pilling, and a dry product can be preferably used. It is preferable to use an acetic acid solution made from plants such as wood vinegar or bamboo vinegar from which harmful substances have been removed by distillation purification.

<Production method using extraction method with butylene glycol solution>
FIG. 1 is a flow chart showing a production method using an extraction step with a butylene glycol solution of Example 1.
The skin disease therapeutic agent of Example 1 is manufactured using an extraction step with a butylene glycol solution as shown in the manufacturing method of FIG. Collect the sap of the bark of the plant of the genus Orranaceae. This sap is dried to produce a vegetable rubber resin (drying step). This dried caustic resin has a reddish brown color.

  Extraction is performed from this gallic resin with a 40% to 70% by weight butylene glycol solution (extraction step). Examples of the extract of the pesticide obtained by this extraction include a liquid component in which at least a part of the pesticide resin is dissolved, a liquid component obtained by concentrating or diluting the resin, or a solid component obtained therefrom by a conventional method.

  For the dissolution of the pilling resin, for example, the pilling resin is introduced into a solution of 40% to 70% by weight of butylene glycol in an amount of usually 0.1 to 60% by weight, preferably about 0.5 to 30% by weight. It can be carried out by stirring as necessary. It is preferable to perform dissolution of such a pilling resin under the temperature conditions of usually 5 to 75 ° C and 10 to 50 ° C. When the temperature condition for dissolution is less than 5 ° C, the solubility of the component derived from the pilling resin is low and extraction may be insufficient. When the temperature exceeds 75 ° C, among the components derived from the pilling resin, the volatility is high. Ingredients volatilize, and there may be cases where the active ingredient cannot be fully utilized in a therapeutic agent for skin diseases.

  The extraction step may be performed under the condition that at least a part of the component derived from the pilling resin is dissolved in a solution of 40% by weight to 70% by weight of butylene glycol, and is not particularly limited. It is desirable to carry out the reaction under the condition that 5 wt% or more, preferably 7 wt% or more, more preferably about 7 to 30 wt% of the introduced pesticide resin is dissolved in a 70 wt% butylene glycol solution.

  The amount of the pesticide resin dissolved in a 40% to 70% by weight solution of butylene glycol can be determined by the difference in weight between the introduced pesticide resin and the pesticide resin removed as an insoluble matter. The insoluble matter can be removed by a known method such as decantation, filtration, and centrifugation. It is preferable to carry out filtration for the purpose of effectively using an extract of the gallic resin in which the gallic resin is dissolved. In the thus obtained extract of the pill, a component having a skin inflammation-inhibiting action contained in the pill resin is contained.

  Thus, the pill extract obtained by extracting from the pill resin with a 40% by weight to 70% by weight butylene glycol solution can be used as it is as an active ingredient of the skin disease therapeutic agent for the preparation of the skin disease therapeutic agent. However, you may remove and use at least one part of the butylene glycol solution which is an extraction solvent (concentration process). The concentration step may be performed by any method, but can be easily performed by concentration under reduced pressure or heating under reflux, and can be performed by concentration under reduced pressure.

  When a pesticide extract extracted with a 40% to 70% by weight butylene glycol solution is concentrated by vacuum concentration or the like, butylene glycol and water as solvents are removed, and one of the volatile components derived from the pesticide is removed. However, the concentrated extract can be preferably used as an active ingredient of a therapeutic agent for skin diseases. Further, in the skin disease therapeutic agent of the present invention, since the fragrance and refreshing feeling due to the volatile components derived from the pills act suitably, the extract extracted as a 40% to 70% by weight butylene glycol solution is concentrated. It is also preferable to contain it as an active ingredient as it is.

  The pyroligneous acid extract obtained by extracting with the butylene glycol solution was mixed with the wood vinegar solution. This wood vinegar liquid is a vinegar liquid that has collected, cooled, and liquefied smoke generated when charcoal is burned. There is also a distilled wood vinegar solution in which impurities from the crude wood vinegar solution are removed and the liquid obtained by distillation contains a lot of natural organic acids. Acetic acid, which is the main component of wood vinegar, has functions such as sterilization, suppression of inflammation, and itching, and it is effective for skin problems such as atopic dermatitis, dry skin, ash and athlete's foot.

  Alternatively, bamboo vinegar may be mixed with the pill extract instead of wood vinegar. Bamboo vinegar is a vinegar that is collected by cooling and liquefying the smoke produced when bamboo is steamed and carbonized. Bamboo vinegar is effective when it is applied to affected areas such as insects, sunburn, burns, etc., to suppress inflammation and relieve pain.

  The mixing ratio of the gallic extract and the acetic acid solution made from plants such as wood vinegar or bamboo vinegar is blended in the range of 0.5-2 for the ratio of acetic acid to the ratio 1 of the gallic extract. it can. The optimal ratio is 1 for the acetic acid solution relative to 1 for the ratio of the pill extract.

<Use of emulsifier>
It is preferable to use an emulsifier when an acetic acid solution such as a wood vinegar solution or a bamboo vinegar solution is added to the pesticide extract. For example, emulsifiers such as glycerin fatty acid ester, lecithin and higher fatty acid monoglyceride are used. Thus, by using an emulsifier during production, the skin disease therapeutic agent of the present invention reduces the surface tension, spreads the liquid (skin disease therapeutic agent) on the surface of the solid (skin), and passes through the gap to the inside. Easy to penetrate (wet and permeate). Moreover, although it is a secondary use, some fatty acid esters of emulsifiers have an action of inhibiting the growth of mold, yeast, gram-positive bacteria, etc. (antibacterial properties).

<Production method using extraction step with ethanol solution>
FIG. 2 is a flow chart showing a production method using an extraction process with an ethanol solution of Example 2.
The skin disease therapeutic agent of Example 2 is manufactured using an extraction step with an ethanol solution as shown in the manufacturing method of FIG. For the extraction of the gallic resin, ethanol can be used as shown below. Extraction is performed from the gallic resin with a 40 wt% to 70 wt% ethanol solution (extraction step). Examples of the extract of the pesticide obtained by this extraction include a liquid component in which at least a part of the pesticide resin is dissolved, a liquid component obtained by concentrating or diluting the resin, or a solid component obtained therefrom by a conventional method. Here, 40 wt% to 70 wt% ethanol solution, preferably 50 wt% to 80 wt% ethanol solution is suitably used.

  For the dissolution of the pilling resin, for example, the pilling resin is introduced into a solution of 40% to 70% by weight of ethanol in an amount of usually 0.1 to 60% by weight, preferably about 0.5 to 30% by weight. It can be carried out by stirring as necessary. It is preferable to perform dissolution of such a pilling resin under the temperature conditions of usually 5 to 75 ° C and 10 to 50 ° C. When the temperature condition for dissolution is less than 5 ° C, the solubility of the component derived from the pilling resin is low and extraction may be insufficient. When the temperature exceeds 75 ° C, among the components derived from the pilling resin, the volatility is high. Ingredients volatilize, and there may be cases where the active ingredient cannot be fully utilized in a therapeutic agent for skin diseases.

  The extraction step may be performed under the condition that at least a part of the components derived from the pilling resin is dissolved in a 40 wt% to 70 wt% ethanol solution, and is not particularly limited, but is 40 wt% to 70 wt%. It is desirable to carry out the reaction under a condition that 5% by weight or more, preferably 7% by weight or more, more preferably about 7 to 30% by weight of the introduced pesticide resin is dissolved in a 1% ethanol solution.

  The amount of the pesticide resin dissolved in the 40% to 70% by weight ethanol solution can be determined by the difference in weight between the introduced pesticide resin and the pesticide resin removed as an insoluble matter. The insoluble matter can be removed by a known method such as decantation, filtration, and centrifugation. It is preferable to carry out filtration for the purpose of effectively using an extract of the gallic resin in which the gallic resin is dissolved. In the thus obtained extract of the pill, a component having a skin inflammation-inhibiting action contained in the pill resin is contained.

  Thus, the extract of the pills obtained by extracting from the pills resin with a 40 wt% to 70 wt% ethanol solution can be used as it is as an active ingredient of the dermatological treatment agent for the preparation of the dermatological treatment agent. The ethanol solution that is the extraction solvent may be removed and concentrated for use (concentration step). The concentration step may be performed by any method, but can be easily performed by concentration under reduced pressure or heating under reflux, and can be performed by concentration under reduced pressure.

  When a pesticide extract extracted with a 40 wt% to 70 wt% ethanol solution is concentrated by vacuum concentration or the like, the solvent ethanol and water are removed, and some of the volatile components derived from the pesticide are also removed. Although it is removed, the concentrated extract can be suitably used as an active ingredient of a therapeutic agent for skin diseases. Moreover, in the skin disease therapeutic agent of this invention, since the fragrance and refreshing feeling by a volatile component derived from a pilling act suitably, the extract extracted as a 40 wt%-70 wt% ethanol solution is not concentrated. It is also preferable to contain it as an active ingredient.

Thus, the wood vinegar liquid or the bamboo vinegar liquid was mixed with the pesticide extract obtained by extraction with the ethanol solution. When adding this acetic acid solution, it is preferable to use an emulsifier.
The mixing ratio of the gallic extract and the acetic acid solution made from plants such as wood vinegar or bamboo vinegar is blended in the range of 0.5-2 for the ratio of acetic acid to the ratio 1 of the gallic extract. it can. The optimal ratio is 1 for the acetic acid solution relative to 1 for the ratio of the pill extract.

<Properties of skin disease treatment agent>
The therapeutic agent for skin diseases of the present invention is not particularly limited depending on the dosage form, symptoms, use site, and the like, but is 40 wt% to 70 wt% butylene glycol solution or 40 wt% to 70 wt% ethanol solution. Ingredient extract obtained by extraction contains a component that suppresses skin inflammation and a component that suppresses skin itch, among components derived from a pesticide resin, and conversely a component that exacerbates inflammation such as tar. It is desirable to contain as little as possible.

The therapeutic agent for skin diseases of the present invention is effective for the treatment of skin diseases such as atopic dermatitis, eczema, urticaria, psoriasis, urticaria, trauma, burns, insect bites, rashes, rashes, and sensitive skin. It can be preferably used as a therapeutic agent for flames. It is also effective as a therapeutic agent for skin diseases for pets.
It can also be used as a skin care cream, milky lotion, and lotion.

  The skin disease therapeutic agent of the present invention is not particularly limited as long as it is a dosage form that can be applied to affected areas of skin diseases such as atopic dermatitis, for example, liquids, creams, emulsions, Ointments and poultices are preferred.

  The therapeutic agent for skin diseases of the present invention may contain a pesticide extract alone as an active ingredient, or may be contained together with other pharmaceutical ingredients.

<Bromelain formulation>
It is also possible to mix bromelain with the skin disease therapeutic agent of the present invention. Bromelain has the effect of degrading proteins by proteolytic enzymes and removing necrotic tissue on the wound surface. It is usually used to promote the decomposition, removal, and cleaning of necrotic tissue on wound surfaces such as burns, pressure ulcers (bed sores), various superficial ulcers, contusions, incision wounds, amputation wounds, and suppurations.

When the therapeutic agent for skin diseases of the present invention is used for severe atopic dermatitis, a therapeutic agent in which an appropriate amount of bromelain is mixed with a mixture of a pill extract and a wood vinegar is effective. When suffering from severe atopic dermatitis, especially atopic dermatitis for a long period of time, there is necrotic tissue whose skin surface is hard and raised like a scab. Even if you apply a therapeutic agent, it is difficult for the active ingredient to penetrate the affected area.
It may take a long time to heal or it may be difficult to achieve a healing effect. Bromelain is a proteolytic enzyme and is also used as a necrotic tissue removal agent. The effect of this treatment softens the affected tissue and allows penetration of the active ingredients of the pesticide and pyroligneous acid into the affected area, thereby increasing the therapeutic effect of severe atopic dermatitis. Moreover, since bromelain also has an anti-inflammatory action, a synergistic effect can be expected when used in combination with a pesticide extract and a wood vinegar.

<Dosage form of skin disease treatment agent>
The skin disease therapeutic agent of the present invention is not particularly limited as long as it is a dosage form that can be applied to affected areas of skin diseases such as atopic dermatitis, for example, liquids, creams, emulsions, Ointments and poultices are preferred. Of these, an ointment is most preferable as a therapeutic agent for skin diseases.

  To make an ointment as a therapeutic agent for skin diseases, white petrolatum must be mixed and dissolved with a pill extract and a wood vinegar solution, but a pill extract and wood vinegar obtained by extraction with an ethanol solution or a butylene glycol solution. Since the liquid contains moisture, it does not fuse with oily white petrolatum.

  Therefore, by mixing an appropriate amount of an emulsifier with white petrolatum, a pesticide extract, and a wood vinegar solution, it is possible to mix moisture and oil that are not originally mixed. By using an emulsifier, the pill extract and the wood vinegar can be uniformly dissolved in white petrolatum, and a skin disease therapeutic agent of uniform quality can be obtained. The emulsifier to be used is preferably a plant having little irritation to the skin.

<Manufacturing process of skin disease treatment ointment>
The skin disease treatment ointment of the present invention is produced, for example, by the following method.
(1) A predetermined amount of white petrolatum is put into the container. (2) The container is heated (boiled) to melt the white petrolatum in it.
(3) A predetermined amount of an emulsified wax and a mixture of a pill extract and a pyroligneous acid solution is put into molten white petrolatum.
(4) Stir well with white petrolatum until the emulsified wax and the mixture of the pill extract and the wood vinegar are sufficiently dissolved. This completes the skin disease treatment ointment preparation of the present invention.
(5) A predetermined amount of therapeutic agent is individually weighed into a product container, and after cooling, the lid is closed to complete the product.

The fact that the myrrh resin-derived component contains a skin inflammation-inhibiting component will be specifically described. However, the present invention is not limited to these examples.
Conditioning agent 1 (Preparation of dip resin extract)
The skin disease treatment agent of Conditioner 1 was obtained by pulverizing a dried product of a pesticide resin with a mortar to obtain a powdery pesticide resin. It is a therapeutic agent for skin diseases obtained by putting 10 g of the obtained powdered gallic resin in 1,000 ml of pure ethanol at 20 ° C., stirring and filtering at room temperature, and using the filtrate as the gallic resin extract. The solid content after filtration was 8.6 g.

FIG. 3 is a graph showing the skin inflammation inhibitory effect of the skin disease therapeutic agent of the present invention.
The graph of FIG. 3 shows the measured value of the ear thickness of the test animal corresponding to the type of ointment applied by the test animal. In white petrolatum, the pesticide resin extract obtained in Conditioner 1 was mixed in amounts of 5% (v / w), 2.5% (v / w), and 1.25% (v / w), respectively. A 5% pilling ointment, a 2.5% pilling ointment, and a 1.25% pilling ointment were prepared.
<Verification of symptom improvement effect of dermatitis>
A 6-week-old SD male rat fed with a free solid diet on a 12-hour light-dark cycle from 8 o'clock to 20 o'clock in a light-dark cycle was divided into 3 test animals for each of the A to F groups. did. The breeding conditions were the same after the start of the trial.

  On the evening of the first day, the ointments shown in Table 1 were applied to the left and right auricles of each test animal (pre-induction ointment application). However, the application was not performed for the test animals of Group A, which was a control experiment. In addition, the positive control used as an application ointment of the group B is a commercially available drug used as a therapeutic drug for atopic dermatitis and contains betamazone valerate which is a corticosteroid. Moreover, the white petrolatum used as the application ointment of the group C is the same as that used as the base material of the pilling ointment.

  On the second day (the day after each ointment was applied), an acetone solution containing 20% picrylchlori, an antigen that induces dermatitis, was applied to the front and back of the left and right auricles of each test animal to induce dermatitis. . In the evening of the day when dermatitis was induced, each test animal was applied with the ointment shown in Table 1 in the same manner as the first day (post-induction ointment application).

  The left and right auricle thickness of each test animal was measured 6 hours after the induction of inflammation.

  On the evening of the third day, the ointment shown in Table 1 was applied to the front and back of the left and right auricles of each test animal in the same manner as on the first day (pre-induction ointment application). On the 4th day, in the same manner as on the 2nd day, dermatitis induction and post-induction ointment application were performed, and the left and right auricle thicknesses were measured 6 hours after the induction.

  In the above experiment, two measurement results were obtained for each of the three test animals in each group. FIG. 3 is a graph showing the result of averaging these to obtain the average pinna thickness of each group.

  As shown in the skin inflammation inhibitory effect graph of FIG. 3, than group A of dermatitis not using an ointment, group B using a positive control which is a commercial ointment, and group C using only white petrolatum as a base material It can be seen that the D, E, and F groups to which the ointment containing the pill was applied had a small thickness of the auricle and suppressed skin inflammation. Among the D, E, and F groups coated with an ointment containing an pill, the F group using a 1.25% dip ointment with a low concentration of pill extract has the smallest thickness of the auricle and has skin irritation. It turns out that it was suppressed, and it turns out that 1.25% ointment has a more preferable active ingredient density | concentration among the ointment ointments used in Example 1. FIG.

FIG. 4 is a photograph showing a situation in which a sweet juice-like surface has emerged on the affected surface after a predetermined time has elapsed after applying the skin disease therapeutic agent of the present invention to the affected area.
Conditioning agent 2 for treating skin diseases is a mixture of cabbage extract and pesticide extract obtained by extraction with 40% to 70% by weight ethanol solution in 500g white petrolatum. It is a skin disease treatment agent obtained by thoroughly stirring. The preparation 2 for treating skin diseases was Reagent A as an ointment.
Initially, a reagent was prepared with a simple extract of the pill and tested for many skin diseases in Myanmar. A healing effect on skin diseases was found. However, since some cases were found to be ineffective or ineffective, it was judged to be incomplete as a therapeutic agent for skin diseases.

  Considering that there is nothing to supplement the skin disease healing effect of the pill extract, select several sterilized and anti-inflammatory materials from natural materials, mix the pill extract and those materials, and use each reagent. Was made.

  When these reagents were tested in Myanmar, the one with the highest healing effect for skin diseases was a reagent made from a mixture of a pesticide extract and wood vinegar.

When the affected area was observed closely, it was found that after applying a reagent prepared with a mixture of a pesticide extract and a pyroligneous acid solution, something like sweet juice emerged on the affected surface after a while.
Such a phenomenon was not observed with the reagent of the pill extract. Perhaps, the component of the pyroligneous acid solution has a function of sucking out toxins in the body.

  For the formulation of the above reagent A, several types of formulated reagents were prepared and used for the inventor's own skin disease (psoriasis), and the one with the most effective psoriasis improvement and anti-itching effect was employed.

<Description of treatment status>
Next, the treatment status of a plurality of persons using the reagent A for treating skin diseases of the present invention will be described.
Treatment example (a) 5-year-old girl:
FIG. 5 is a photograph in which the therapeutic agent for skin disease of the present invention was applied to the head of a 5-year-old girl, and (a) is a state before treatment, and (b) is a state 30 days after treatment. .
As shown in the figure, this reagent A was applied once a day to a 5-year-old girl who had suppurated the entire head, had a scab, and had no hair. After 18 days, about 70% of the inflamed part improved and the hair grew. After 30 days, most of the suppuration caused by inflammation improved.

Treatment example (b) Myanmar children (2-13 years old):
This reagent A was applied once a day to 7 children (2 to 13 years old) in an orphanage in Myanmar. The children suffered from atopic dermatitis, trauma, and insect bites that had suppurated and were unable to sleep at night due to severe itching and pain. A commercial ointment was applied, but it did not improve at all. It was confirmed that the itch and pain of the affected area were eased immediately after the start of treatment with this reagent A, and the inflamed part of the trunk was reduced and improved after 3 to 5 days. After 18 days, the affected areas of all the children were improved and inflammation and suppuration were almost eliminated.

  FIG. 6 to FIG. 14 are photographs showing the state of treatment by applying the skin disease therapeutic agent of the present invention to the affected part, (a) is the state before treatment, and (b) is the state after treatment. FIG. 6 is a photograph showing a state of treatment by applying to the back of a 9-year-old boy's hand. FIG. 7 is a photograph showing a state where the abdominal wound of a 9-year-old boy was applied and treated at the place where the suppuration occurred. FIG. 8 is a photograph showing a state in which the therapeutic agent for skin disease of the present invention is applied to a site where a wound of a finger of a 18-year-old boy has been treated, and (a) is a state before treatment, and (b) is a treatment. It is a later state. FIG. 9 is a photograph showing a state where the wound on the back of the head of a one-and-a-half-year-old girl's baby was applied and treated. FIG. 10 is a photograph showing a state in which the wound on the back of the back of a two-and-a-half-year-old girl's baby was applied and treated. FIG. 11 is a photograph showing a state of application and treatment on the back of the head of a 13-year-old boy. FIG. 12 is a photograph showing a state of treatment by applying to the abdomen of a 15-year-old boy. FIG. 13 is a photograph showing a state of treatment applied to the arm and palm of a 13-year-old boy. FIG. 14 is a photograph showing a state of application and treatment around the mouth of a 12-year-old girl.

Treatment example (c) 46 year old woman:
For many years, she suffered from atopic dermatitis around her neck and face, suffered from severe itching, and the affected area was red and swollen, and she was reluctant to go out.
I have been treated with steroids, but my symptoms improved temporarily, but after a while, it recurred. I gave up treatment for a few years because I was afraid of the side effects of steroids.
After the treatment with this reagent A was started, the itch disappeared within a few days, and after 2 weeks, the inflammatory part of the affected area was swollen and withered. One month later, there were some traces of treatment, but it was almost completely cured.

Treatment example (d) Adult male:
Since the inventor of the present invention pierced the hand with a caterpillar while working in the garden and felt a throbbing and intense pain, reagent A was immediately applied to the place where the caterpillar was stabbed. After a while, something like sweet juice appeared on the surface of the affected area, and the pain disappeared.

  The skin disease treatment agent of Conditioner 3 is a mixture of a pesticide extract and a wood vinegar solution obtained by extraction with 40% to 70% by weight of a butylene glycol solution in 500 g of white petrolatum bathed in water. It is a skin disease treatment agent obtained by adding 5 cc and stirring well. The preparation 3 for treating skin diseases was reagent B as an ointment.

Treatment example (e) Buddhist monks at a temple in Myanmar Since skin diseases also spread to Buddhist monks at a temple in Myanmar, this reagent B was applied to the affected areas of 10 Buddhist monks once a day. Immediately after the start of treatment with this reagent B, itching and pain in the affected area eased, and after 9 days, the inflamed area of all affected areas was reduced or almost completely cured.
We received a request from a temple monk who was looking at the results that we wanted to commercialize it as soon as possible. It was confirmed that this reagent B has the same therapeutic effect on skin diseases as the present reagent A.

Treatment example (f) 13 year old boy:
Eczema, which seems to be atopic dermatitis, was formed on both armpits and around the neck, and the skin surface swelled red and suffered from severe itching. After treatment with this reagent B, itching eased immediately after, and swelling of the affected area subsided several days later. After 2 weeks, the skin swells and the inflammation has subsided. One month later, treatment marks remained, but almost completely cured.

  In addition, the present invention can reduce the manufacturing time and the manufacturing cost by using an extract having a bactericidal and antibacterial effect when extracting a pill of a vegetable rubber resin, and atopic dermatitis If it is the structure which can suppress itch and inflammation more effectively, it will not be limited to embodiment of the invention mentioned above, Of course, it can change variously in the range which does not deviate from the summary of this invention.

  The therapeutic agent for skin diseases of the present invention can be used for treating skin diseases associated with itching and inflammation such as atopic dermatitis, eczema and rash.

Claims (7)

A pesticide extract obtained by dissolving at least a part of a pesticide resin in a 40 wt% to 70 wt% butylene glycol solution at a temperature condition of 10 to 50 ° C ;
And acetic acid solution the plants such as wood vinegar or bamboo vinegar solution as a raw material, is the active ingredient,
The mixing ratio of the gallic extract and the acetic acid solution is such that the ratio of the acetic acid solution is 0.5 to 2 with respect to the ratio 1 of the gallic extract,
A part of the butylene glycol solution used in the extract contains as a moisturizing active ingredient , a skin disease therapeutic agent. In a temperature condition of 10 to 50 ° C., a pesticide extract obtained by dissolving at least part of a pesticide resin in a 40 wt% to 70 wt% ethanol solution;
And acetic acid solution the plants such as wood vinegar or bamboo vinegar solution as a raw material, is contained in be the active ingredient,
The mixing ratio of the gallic extract and the acetic acid solution is such that the ratio of the acetic acid solution is 0.5 to 2 with respect to the ratio 1 of the gallic extract,
A part of said ethanol solution used for an extract contains as a sterilizing active ingredient having volatility , a skin disease therapeutic agent characterized by the above-mentioned. The skin disease therapeutic agent according to claim 1, wherein bromelain is blended in the skin disease therapeutic agent. Dosage form of the skin disease therapeutic agent, solutions, creams, emulsions, is either ointments or poultices, cutaneous according to any one of claims 1, 2 or 3, characterized in that Disease treatment agent. Dry the bark of the plants of the genus Myrranaceae to produce a pesticide resin,
In the temperature condition of 10-50 ° C. with a butylene glycol solution, extract the pilling extract from the pilling resin,
Partial concentration of the pill extract , leaving the extract extracted as the butylene glycol solution as a moisturizing active ingredient,
An acetic acid solution made from a plant such as wood vinegar or bamboo vinegar is used as the gallic extract , and the acetic acid solution has a mixing ratio of the gallic extract and the acetic acid with respect to the ratio 1 of the gallic extract. A method for producing a therapeutic agent for skin diseases, characterized in that the ratio is 0.5 to 2 . Dry the bark of the plants of the genus Myrranaceae to produce a pesticide resin,
In the temperature condition of 10-50 ° C. with an ethanol solution, the pilling solution is extracted from the pilling resin,
Concentrating part of the pill extract , leaving the extract extracted as the ethanol solution as a sterilizing active ingredient having volatility,
An acetic acid solution made from a plant such as wood vinegar or bamboo vinegar is used as the gallic extract , and the acetic acid solution has a mixing ratio of the gallic extract and the acetic acid with respect to the ratio 1 of the gallic extract. A method for producing a therapeutic agent for skin diseases, characterized in that the ratio is 0.5 to 2 . The method for producing a therapeutic agent for skin diseases according to any one of claims 5 and 6 , wherein an emulsifier is used when an acetic acid solution such as a wood vinegar solution or a bamboo vinegar solution is added to the pill extract. .

Images